Hyperhomocysteinemia associated with decreased renal transsulfuration activity in Dahl S rats

被引:37
|
作者
Li, Ningjun
Chen, Li
Muh, Rachel W.
Li, Pin-Lan
机构
[1] Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA
[2] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA
关键词
hypertension genetic; glomerulosclerosis; cardiovascular diseases;
D O I
10.1161/01.HYP.0000219634.83928.6e
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Elevated plasma homocysteine (Hcys) has been reported to participate in the development of arterial and glomerular sclerosis in Dahl salt-sensitive hypertensive ( SS) rats. The mechanism resulting in hyperhomocysteinemia in these animals remains unknown. Disposal of Hcys in the kidneys plays an important role in regulating the plasma Hcys level. We, therefore, examined the activities and expressions of the enzymes involved in the metabolism of Hcys in the kidneys of SS rats, compared with that of Brown Norway rats and SSBN13 rats, a consomic subcolony of SS rats that carries a substituted chromosome 13 from Brown Norway rats. High-performance liquid chromatography analysis demonstrated that plasma Hcys levels were significantly higher in SS rats. The conversion of S-adenosylhomocysteine into Hcys via S-adenosylhomocysteine hydrolase by renal tissue was not different among these 3 rat strains. However, the metabolic rate of Hcys into cysteine was markedly reduced in the SS rat kidneys. The mRNA and protein levels of cystathionine beta-synthase (CBS), one of the key enzymes in the transsulfuration pathway in the kidneys, were significantly lower in SS rats. In microdissected nephron segments, CBS mRNA was shown to be mainly present in renal proximal tubules (PTs). The mRNA levels of CBS in the PTs were also significantly decreased in SS rats, accompanied by a reduced CBS activity in PTs. We conclude that hyperhomocysteinemia is associated with a decreased activity and expression of CBS in renal PTs because of the defect of chromosome 13 in SS rats.
引用
收藏
页码:1094 / 1100
页数:7
相关论文
共 50 条
  • [31] Decreased arginase activity in the kidney of Dahl salt sensitive rat
    Iwata, S
    Harada, H
    Nonaka, H
    Kitazaki, K
    Watari, Y
    Tsujino, T
    CIRCULATION, 1998, 98 (17) : 725 - 725
  • [32] Altered renal adenosine metabolism and glomerular hypertension in Dahl S/Jr rats.
    Zou, AP
    Nithipatikom, K
    Li, PL
    Roman, RJ
    Cowley, AW
    FASEB JOURNAL, 1997, 11 (03): : 491 - 491
  • [33] Induction of renal P4504A activity with clofibrate normalizes pressure-natriuresis and prevents hypertension in Dahl S rats
    AlonsoGalicia, M
    Frohlich, B
    Roman, RJ
    HYPERTENSION, 1997, 30 (03) : P161 - P161
  • [34] DERANGEMENTS OF RENAL MICROCIRCULATORY RESPONSIVENESS IN DAHL RATS - IMPLICATIONS FOR RENAL INJURY
    TAKENAKA, T
    FORSTER, H
    DEMICHELI, A
    EPSTEIN, M
    CLINICAL RESEARCH, 1991, 39 (02): : A350 - A350
  • [35] Mycophenolate Mofetil Prevents Renal Injury in Dahl S Rats on High Fat Diet
    Spradley, Frank T.
    De Miguel, Carmen
    Pollock, David M.
    Pollock, Jennifer S.
    HYPERTENSION, 2011, 58 (05) : E134 - E134
  • [36] Evidence that reduced renal medullary NOS activity of Dahl S rats enables small elevations of Avp to produce sustained hypertension
    Yuan, B
    Cowley, AW
    HYPERTENSION, 2000, 36 (04) : 682 - 682
  • [37] RENAL NERVES, SODIUM-BALANCE AND DEVELOPMENT OF HYPERTENSION IN DAHL-S RATS
    OSBORN, JL
    EWENS, JD
    ROMAN, RJ
    FEDERATION PROCEEDINGS, 1986, 45 (03) : 522 - 522
  • [38] Renal uptake and excretion of homocysteine in rats with acute hyperhomocysteinemia
    House, JD
    Brosnan, ME
    Brosnan, JT
    KIDNEY INTERNATIONAL, 1998, 54 (05) : 1601 - 1607
  • [39] EFFECT OF SALT ON RENAL PROSTAGLANDIN RECEPTORS OF DAHL RATS
    LIMAS, C
    LIMAS, CJ
    CIRCULATION, 1983, 68 (04) : 383 - 383
  • [40] Prevention of hypertension and renal dysfunction in Dahl rats by α-tocopherol
    Forde, P
    Scribner, AW
    Dial, R
    Loscalzo, J
    Trolliet, MR
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 42 (01) : 82 - 88